Compare Centrus Energy Corp (LEU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs GeneDx Holdings Corp — how do they compare? Centrus Energy Corp trades at $142.44 (market cap $2.91B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Centrus Energy Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and GeneDx Holdings Corp for 19 Days on average.
| LEU | WGS | |
|---|---|---|
Market Cap | $2.91B | $2.02B |
Volume | 903,777 | 734,640 |
Sector | Energy | Health |
52-Week High | $436.00 | $167.51 |
52-Week Low | $138.18 | $34.51 |
Typical Hold Time | 29 Days | 19 Days |
Enterprise Value | $2.22B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $142.09, down 3.43% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings with an EPS beat but faces declining profitability margins year-over-year. Recent news highlights Centrus' strategic position as the sole US-licensed producer of high-assay low-enriched uranium (HALEU), securing multiple supply contracts amid growing nuclear energy demand.
Outlook: LEU offers exposure to the nuclear fuel supply chain with strong analyst support (46% buy ratings) and a $218.10 consensus price target. Key risks include execution challenges, volatile cash flows, and high valuation multiples (P/E 75.18). The stock's near-term performance hinges on operational execution and contract ramp-up.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
